JP2020524149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524149A5 JP2020524149A5 JP2019569878A JP2019569878A JP2020524149A5 JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5 JP 2019569878 A JP2019569878 A JP 2019569878A JP 2019569878 A JP2019569878 A JP 2019569878A JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- treg
- breg
- cancer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522167P | 2017-06-20 | 2017-06-20 | |
| US62/522,167 | 2017-06-20 | ||
| US201762573264P | 2017-10-17 | 2017-10-17 | |
| US62/573,264 | 2017-10-17 | ||
| US201862677265P | 2018-05-29 | 2018-05-29 | |
| US62/677,265 | 2018-05-29 | ||
| PCT/US2018/038490 WO2018236995A2 (en) | 2017-06-20 | 2018-06-20 | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524149A JP2020524149A (ja) | 2020-08-13 |
| JP2020524149A5 true JP2020524149A5 (https=) | 2021-07-29 |
| JP7843113B2 JP7843113B2 (ja) | 2026-04-09 |
Family
ID=64735842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569878A Active JP7843113B2 (ja) | 2017-06-20 | 2018-06-20 | Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12005073B2 (https=) |
| EP (1) | EP3642243A4 (https=) |
| JP (1) | JP7843113B2 (https=) |
| CN (1) | CN110945030A (https=) |
| AU (1) | AU2018289493B2 (https=) |
| CA (1) | CA3064632A1 (https=) |
| WO (1) | WO2018236995A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110192106B (zh) * | 2017-01-16 | 2021-09-28 | 株式会社岛津制作所 | 数据解析装置以及数据解析用程序 |
| CA3064632A1 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| EP3887548A1 (en) * | 2018-11-30 | 2021-10-06 | GBG Forschungs GmbH | Method for predicting the response to cancer immunotherapy in cancer patients |
| SG11202113008YA (en) * | 2019-05-31 | 2021-12-30 | Medimmune Llc | Combination therapy |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CN113368262A (zh) * | 2020-09-03 | 2021-09-10 | 上海易慕峰生物科技有限公司 | 通过实体肿瘤转移动物模型获取中间结果的方法 |
| WO2022048314A1 (zh) * | 2020-09-03 | 2022-03-10 | 上海易慕峰生物科技有限公司 | 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用 |
| JP2023549023A (ja) * | 2020-09-29 | 2023-11-22 | パーデュー・リサーチ・ファウンデーション | クルクソンジテルペノイドおよびその使用法 |
| CN113278619B (zh) * | 2021-07-19 | 2021-10-15 | 广东省农业科学院动物科学研究所 | 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法 |
| CN114147343B (zh) * | 2021-12-08 | 2024-08-16 | 西安中科微精光子科技股份有限公司 | 一种激光加工方法、系统及计算机存储介质 |
| CN118126196B (zh) * | 2024-03-06 | 2024-08-16 | 中国医学科学院基础医学研究所 | 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用 |
| CN120843525B (zh) * | 2025-09-23 | 2025-12-09 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001087977A2 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| CA2429814C (en) * | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| CN101323643B (zh) * | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| WO2010075249A2 (en) * | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2488200A4 (en) * | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CA3064632A1 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
-
2018
- 2018-06-20 CA CA3064632A patent/CA3064632A1/en active Pending
- 2018-06-20 AU AU2018289493A patent/AU2018289493B2/en active Active
- 2018-06-20 WO PCT/US2018/038490 patent/WO2018236995A2/en not_active Ceased
- 2018-06-20 US US16/612,938 patent/US12005073B2/en active Active
- 2018-06-20 CN CN201880048338.0A patent/CN110945030A/zh active Pending
- 2018-06-20 EP EP18820336.8A patent/EP3642243A4/en active Pending
- 2018-06-20 JP JP2019569878A patent/JP7843113B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524149A5 (https=) | ||
| AU2023203601B2 (en) | Ex vivo bite-activated T cells | |
| Stein et al. | Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation | |
| CN104427992B (zh) | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 | |
| JP2022513685A (ja) | 養子細胞療法を用いた処置のための方法 | |
| US20220169694A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| JP2021524240A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP2016509582A5 (https=) | ||
| Michelakos et al. | B7-H3 targeted antibody-based immunotherapy of malignant diseases | |
| US20240110230A1 (en) | Biomarkers for cancer treatment | |
| US20260109766A1 (en) | Lag-3 antagonist therapy for melanoma | |
| CN114206346A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| US20210252036A1 (en) | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) | |
| US20240252633A1 (en) | Methods of treating cancer with cd-40 agonists | |
| Stock et al. | Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma | |
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| US20250290154A1 (en) | Predictive markers for immunotherapy | |
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| Gross et al. | CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease | |
| HK40115765A (zh) | 从免疫疗法预测不良事件 | |
| WO2026096859A2 (en) | Biomarkers related to immunotherapy efficacy | |
| HK40054961A (en) | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) | |
| HK40096812A (zh) | 离体bite激活的t细胞 |